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Metabolic syndrome is a cluster of related risk factors for cardiovascular disease, type 2 diabetes and liver disease. Obesity, which
has become a global public health problem, is one of the major risk factors for development of metabolic syndrome and type 2
diabetes. Obesity is a complex disease, caused by the interplay between environmental and genetic factors. Ghrelin is one of the
circulating peptides, which stimulates appetite and regulates energy balance, and thus is one of the candidate genes for obesity and
T2DM. During the last years both basic research and genetic association studies have revealed association between the ghrelin gene
and obesity, metabolic syndrome or type 2 diabetes
1.Introduction
A great deal of evidence suggests that ghrelin is involved
in the development of metabolic syndrome and type 2
diabetes (T2DM). Ghrelin plays also an important role
in cardiovascular system. We have examined ghrelin and
its genetic variation with respect to the occurrence of the
components of metabolic syndrome and the risk of T2DM.
In this paper we give an overview of what is known about
the role of ghrelin in obesity, insulin resistance, T2DM,
and cardiovascular disease, and how ghrelin is involved
in the regulation of glucose, insulin, adipose tissue, and
cardiovascular metabolism. We also discuss the putative role
of genetic variation in the ghrelin and ghrelin receptor genes
in metabolic syndrome and T2DM.
2. GhrelinConcentrations in Obesity,Insulin
Resistance,andType2DiabetesMellitus
The recent literature suggests that in addition to food intake
andenergybalance,ghrelinalsocontrolsglucosemetabolism
[1]. Furthermore, current evidence suggests that ghrelin
could contribute to the metabolic syndrome [1]. It has been
shown that ghrelin concentrations are reduced in diﬀerent
pathophysiological conditions including obesity, type 2
diabetes, and other conditions with metabolic disturbances
[2, 3].
Ghrelin is a target for posttranslational modiﬁcations,
which results in two diﬀerent forms of circulating ghrelin:
unacylated ghrelin (UAG) and acylated ghrelin (AG), in
which Ser 3 is octanoylated [4] .Ar e l a t i v ee x c e s so fA G
compared to UAG has been reported in insulin resistance
and related conditions [3] raising the possibility that
UAG/AG ratio could play a role in development of metabolic
syndrome.
Plasmaghrelinconcentrationhasbeenshowntobelower
in obese Caucasians when compared with lean Caucasians
[2, 3, 5, 6], and in some studies higher AG concentrations
have been reported in obese but otherwise healthy subjects
compared to nonobese healthy subjects [3]. In persons with
type 2 diabetes the fasting ghrelin concentrations are lower
in obese than in lean persons and the similar ratio is with AG
concentrations [7]. Circulating ghrelin concentrations are
also reduced in healthy oﬀspring of type 2 diabetic patients
[8] indicating the presence of possible genetic component
in the regulation of ghrelin plasma levels. When the ghrelin
concentrations were compared between lean Caucasians and
lean Pima Indians, it was found that the concentration was2 International Journal of Peptides
signiﬁcantly lower in Pima Indians, the population with high
tendency to obesity and type 2 diabetes [5].
There are also diﬀerences in fasting and postprandial
ghrelin concentrations in nondiabetic populations between
lean and obese persons. Postprandial plasma ghrelin is
suppressed proportional to meal calorie content in normal
weight [9] but not in obese subjects [10], which suggest that
food intake fails to suppress ghrelin levels in obese humans
[11].
Low ghrelin concentrations are also associated with
higher prevalence of the metabolic syndrome with pro-
gressively lower ghrelin levels in relation to the number
of components of the metabolic syndrome [1, 12]. This
is mostly explained by higher BMI in subjects with lower
ghrelin levels, because adiposity inﬂuences all other features
of the metabolic syndrome [1–3, 5, 12–14]. In fact, it
has been shown that total plasma ghrelin as well as UAG
concentrations are lower in obese patients with metabolic
syndrome compared to nonobese counterparts [14]. Fur-
thermore, among obese subjects, plasma ghrelin levels are
lower in insulin resistant persons compared to insulin
sensitive persons [15]. However, the concentrations of total
ghrelin, AG, or UAG separately are not diﬀerent between
insulin sensitive and insulin resistant persons with similar
body weight [1]. Among overweight and obese patients, the
ratio of AG:UAG is lower in insulin sensitive than in insulin
resistant subjects [3, 15].
Polycystic ovary syndrome (PCOS) is associated with
adiposity and metabolic changes predisposing to insulin
resistance and type 2 diabetes mellitus [16–18]. Obese
patients with PCOS have lower levels of ghrelin than BMI
matched control subjects [19], although in another study no
diﬀerence was observed in this regard [20].
3. Effect of Weight Loss on
Ghrelin Concentration
It has been suggested that ghrelin is linked to excessive
food intake in two ways. Firstly, the attenuated postprandial
reduction in ghrelin levels may directly increase the length
of time for which the subject feels hungry, and secondly,
as a consequence of the elevated ghrelin levels, the speed
of gastric emptying may not be reduced, and the resulting
feeling of satiety not elicited [11]. Without these feelings of
satiety, obese individuals eat more than they need, and thus
gain weight [13].
So far, the majority of studies have focused on the eﬀects
of diet induced or combined exercise/diet weight loss on
total ghrelin concentrations [21–28]. These studies are very
diverse, with diﬀerent interventions, intervention periods,
age and number of participants, and also inclusion criteria.
Most studies have shown that weight reduction increases
ghrelin concentrations in obese subjects [21–23, 29] or the
concentration is unchanged in overweight healthy adults
or obese children after weight loss [24]. However, during
weight maintenance after the weight loss, ghrelin levels tend
to decrease back to the levels they were before weight loss
[25]. Furthermore, an initial decrease along with weight loss
and subsequent increase in plasma ghrelin has been reported
[26]. Weight loss is also shown to result in increased ghrelin
concentrations in normal weight individuals [27]. Only a
few studies have been conducted to investigate the exclusive
eﬀect of weight loss through exercise intervention on plasma
ghrelin levels. In general, these studies have shown either an
increase [28] or no change on ghrelin concentrations [30].
4. Effect of Insulinand Glucose Concentrations
on Ghrelin Secretion
Insulin is shown to inhibit ghrelin secretion in healthy
normal-weight and overweight persons [15, 31, 32], and
both oral and intravenous glucose loads are also shown to
regulate ghrelin secretion in humans [33–37]. Insulin and
HOMA-IR are associated negatively with total ghrelin and
UAG concentrations while AG had positive association [3].
Liu and coworkers developed recently a new reliable sand-
wich method for detection of AG and UAG separately. With
this new assay they showed evidence that ghrelin acylation
andsecretionareregulatedseparately.Theuseofthismethod
may facilitate more reliable detection of diﬀerent ghrelin
forms in future [38]. Physiological increases in insulin levels
may play a key role in regulating postprandial plasma ghrelin
concentrations, since meal-induced ghrelin suppression is
absentinsevereinsulindeﬁciency[10].Anincreaseininsulin
after the oral or intravenous glucose administration could
contribute to the inhibitory eﬀect of glucose on ghrelin
concentrations. However, the administration of a combined
pulse of glucose and insulin does not acutely suppress
ghrelinlevels[36–39].Reductioninghrelinafterintravenous
glucose bolus in subjects with type 2 diabetes suggests that
early insulin response does not aﬀect plasma ghrelin [39].
Indeed, during euglycaemic clamp, an increase in insulin
levels leads to suppression of ghrelin levels and is remained
suppressed during subsequent hypoglycemia and even fell
further during following hyperglycaemia. However, another
study has shown that hyperinsulinaemia with concomitant
hyperglycaemia at concentrations typically seen in insulin-
resistant subjects does not aﬀect plasma ghrelin but is
decreased only at pharmacological insulin concentrations
[40]. However, it is still unclear whether insulin and glucose
per se play a direct inhibitory role in ghrelin secretion [16].
The decrease in ghrelin levels after an oral glucose load is
modulated by sex, status of obesity, and level of insulin
resistance [41]. Ghrelin concentrations are shown to be
higher in women than in men. To support of this ﬁnding,
ghrelin concentrations are shown to correlate positively with
testosterone concentrations [41].
5. Effect of Ghrelin on Glucose and
Insulin Metabolism
Above we discussed the associations of ghrelin with glucose
and insulin levels. However, ghrelin may also participate in
theregulationofglucoseandinsulinmetabolismasdiscussed
in this section in more detail. Because glucose and insulin
metabolism are tightly connected, their eﬀects are diﬃcult to
separate from each other.International Journal of Peptides 3
A human study conducted recently in morbidly obese
nondiabetic persons showed that administration of com-
bination of AG and UAG reduced insulin concentrations
signiﬁcantly without any eﬀect on glucose concentrations,
while AG or UAG alone did not have any signiﬁcant eﬀects
[42]. Based on this data, it was concluded that insulin
sensitivity was improved in these persons [42]. It has been
shown that speciﬁcally AG is responsible for improving
insulin sensitivity, while UAG has opposite eﬀects [43].
However, in another study conducted with healthy young
persons showed that administration of ghrelin impairs
insulin and glucose metabolism by increasing glucose
concentrations and decreasing insulin levels [44], and a
number of other studies have supported these ﬁndings
[45–48]
Acuteghrelinadministrationinhumansincreasesplasma
glucose levels by downregulation of insulin, and arginine
is shown to amplify the hyperglycaemic eﬀect of ghrelin
which can be blocked by the administration of the GHS-R
agonist D-(Lys3)-GHRP6. To support these ﬁndings, plasma
ghrelin levels are shown to correlate negatively with insulin
concentrations and are associated with fasting insulin levels,
insulin resistance, and obesity [49, 50]. Speciﬁcally, AG is
shown to be responsible for the decrease in insulin and a
consequent rise in glucose levels [49]. It has been suggested
that UAG alone has been suggested to be devoid of any
endocrine eﬀects but is able to antagonize the eﬀects of AG
on insulin secretion [51]. There is evidence that UAG has
a speciﬁc functional role in insulin signaling since it has
been shown to stimulate insulin secretion in pancreatic cell
lines [52, 53]. Furthermore, the combination of AG and
UAG may improve insulin sensitivity [51]. This has been
shown in GH-deﬁcient patients, in whom UAG prevents the
rapid rise in insulin and glucose levels when coadministered
with AG [51]. The hyperglycaemic eﬀect of ghrelin could
be mediated through activation of catecholamine-induced
glycogenolysis or directly by acting on hepatocytes; where
it may enhance gluconeogenesis [45, 54]. Interestingly, AG
has been shown to stimulate glucose output by primary
hepatocytes;whereasUAGmediatesaninhibitoryeﬀect[49].
Moreover, it counteracts the stimulatory eﬀect of AG on
glucose release [49].
Ghrelin is shown to be expressed in pancreas both in
rodents and humans [55–57], where it may locally modulate
insulin secretion. These ﬁndings suggest that ghrelin has
a pathophysiological role in regulation of insulin release.
Ghrelin is found to inhibit insulin release in rodents and
in isolated islets in vitro [58–60], to promote survival of
both INS-1E β cell line and human islets of Langerhans
[52] and to stimulate insulin secretion in pancreatic cell
lines [52, 53]. Furthermore, ghrelin is shown to prevent cell
death and apoptosis of HIT-T15 pancreatic β cell line [60].
Ghrelin treatment of neonatal rats exposed to streptozotocin
attenuatesthedevelopmentofdiabetesandisassociatedwith
increased islet neogenesis, suggesting that ghrelin might have
a proliferative or cytoprotective eﬀect on β cells [60]. In
mice, ghrelin has also shown to hamper insulin’s capacity
to suppress endogenous glucose production; whereas it
reinforces the action of insulin on glucose disposal [61].
Furthermore,simultaneousadministrationofUAGabolishes
the inhibitory eﬀect of ghrelin on hepatic insulin action [61].
6. Effect of Ghrelin on Adipose Tissue
Adiposetissueisoneofthemostimportantorgansmediating
metabolic eﬀects by numerous adipokines and cytokines,
which are secreted from adipose tissue [62]. There is increas-
ing amount of evidence that also ghrelin may have an impor-
tant role in modulating function of adipose tissue. Because
obesity has a signiﬁcant role in modulating the expression of
ghrelin,itisimportanttoknowhowghrelinisinvolvedinthe
regulationofadipocytemetabolism.Severalstudieshavesug-
gested that ghrelin may play an important role in adipogen-
esis and storage of energy in adipose tissue [63–65]. Chronic
ghrelin administration has been shown to increase body fat
content in rodents and humans [63]. In visceral adipose tis-
sue, ghrelin (AG and UAG) is shown to stimulate lipid accu-
mulation by enhancing the expression of adipogenic genes
including PPARg, SREBP1, acetyl-CoA carboxylase, fatty
acid synthase lipoprotein lipase, perilipin, adipocyte deter-
mination and diﬀerentiation-dependent factor (ADD)1, and
adipose protein 2/fatty acid binding protein (aP2) during
adipocyte diﬀerentiation [66]. These functions might be
mediated via AMPK pathway [67]. It has been demonstrated
that infusion AG and UAG simultaneously in rats inde-
pendently modulates adipocyte metabolism by inhibiting
isoproterenol induced lipolysis [68], regulating adipogenesis
[69, 70], suppressing noradrenalin release in brown adipose
tissue [71], and promoting glucose and triglyceride uptake
and antiapoptotic actions [65]. Ghrelin is also shown to
stimulate lipogenesis and to inhibit lipid oxidation in white
adipocytes; whereas in brown adipocytes central ghrelin
infusion results in decreased expression of uncoupling
proteins, molecules contributing to energy dissipation [69].
All of these ﬁndings strongly support the view that ghrelin
may have an “energy saving” eﬀects on adipose tissue.
In addition, Ghrelin has also been shown to stimulate
adipogenesis in vitro [70, 93], and both AG and UAG
directly promote bone marrow adipogenesis in vivo [70,
93]. However, Zang et al. have shown that ghrelin inhibits
adipogenesis by stimulating cell proliferation in mouse
adipocyte cell line [94]. Ghrelin also inhibits the expression
of adiponectin. It is of note that the reduced concentrations
of adiponectin have been implicated in the pathogenesis
of insulin resistance and obesity [95]. Furthermore, ghrelin
exerts a receptor-mediated stimulatory eﬀect on leptin
production of cultured rat white adipocytes [96].
7. Ghrelinand Immunomodulation
Given the wide distribution of functional GHSR on various
immune cells, it was hypothesized that ghrelin may exert
immunoregulatory eﬀect on immune cell subpopulations
[97]. In vitro, ghrelin treatment is shown to inhibit pro-
duction of proinﬂammatory cytokines (interleukin IL1β,
IL6, and TNFα by PBMCs via a GHSR-speciﬁc pathway
[97]). It was further reported that ghrelin inhibits IL6 and
TNFα mRNA expression in primary human T cells, which4 International Journal of Peptides
Table 1: Common names of GHRL SNPs with their corresponding
rs-numbers.
NCBI RefSNP accession ID Position SNP location
rs1629816 −4427G>AP r o m o t e r
rs3755777 −1500C>GP r o m o t e r
rs26311 −1062G>CP r o m o t e r
rs26312 −994C>TP r o m o t e r
rs27647 −604G/A Promoter
rs26802 −501A/C Promoter
rs696217 Leu72Met Exon 3
rs2075356 3056T>CI n t r o n 3
rs4684677 Gln90Leu Exon 4
rs35684 5179A>G3   region
rs2072578 9344G>A3   region
suggests a role for ghrelin in the transcriptional regulation of
inﬂammatory cytokine expression [98].
8. Effects of Ghrelinon CardiovascularSystem
Ghrelin has diverse cardiovascular eﬀects, which are most
probably ghrelin receptor mediated rather than GH medi-
ated, since expression of ghrelin receptor has been reported
in the cardiovascular system [99]. Administration of ghrelin
in persons with metabolic syndrome is shown to improve
endothelial function by preventing proatherogenic changes
[100] and improving vasodilatation [101], by decreasing
blood pressure (BP) without an increase in heart rate [102],
and additional haemodynamic eﬀects by increasing cardiac
output [103]. Chronic subcutaneous administration of ghre-
lininratsisshowntoexertatherapeuticeﬀectinheartfailure
by improving left ventricular dysfunction and attenuation
of the development of cardiac cachexia [104], by improving
leftventriculardysfunctionandattenuatingthedevelopment
of left ventricular remodeling and cardiac cachexia in rats
withCHF[105]. Plasma ghrelin concentrations are shown to
correlate positively with carotid artery atherosclerosis [106].
In addition, ghrelin receptor is upregulated in heart muscle
of patients suﬀering from end-stage heart failure [106].
Molecular mechanisms for the cardiovascular activity of
ghrelin have been intensively studied in cell culture models
[107, 108]. It has been demonstrated that ghrelin stimulates
nitric oxide (NO) production both in cultured endothelial
cells and in intact vessels [107, 108], while the NO synthesis
can be blocked by NO synthase inhibitor (NOS) (NG nitro-
L-arginine methyl ester), by phosphatidylinositol 3-kinase
inhibitor (wortmannin) or by antagonist of ghrelin receptor
(D-Lys3)[ 107]. Furthermore, ghrelin is shown to mediate
NO production through phosphorylation of endothelial
nitric oxide synthase (eNOS) [108], Akt, one of the main
kinases involved also in insulin signaling pathway [107, 108]
and AMP-activated protein kinase (AMPK), in endothelial
cells and in intact vessels [108]. Based on these ﬁndings
ghrelin uses partly insulin signaling pathway for production
of NO. Furthermore, downregulation of GHSR-1 by siRNA
blocks the NO production and phosphorylation of Akt and
endothelialNOSindicatingthatthesefunctionsaremediated
by GHSR-1 [107].
Togliatto and coworkers [109] studied separately the
eﬀects of AG and UAG on mobilization of endothelial pro-
genitor cells (EPCs) in healthy humans, persons with T2DM,
and in ob/ob mice. They found that the treatments had no
eﬀect in healthy human subjects. However systemic admin-
istration of UAG but not AG prevented diabetes-induced
EPC damage by modulating the NAPDH oxidase regulatory
protein Rac1 and improved their vasculogenic potential both
in individuals with T2DM and ob/ob mice [109]. UAG also
facilitated the recovery of mobilization of EPC. Crucial to
EPC mobilization by UAG was the rescue of NO synthase
phosphorylation by Akt. Furthermore, EPCs expressed UAG
binding sites, which were not recognized by AG [108].
To support earlier ﬁndings above, Tesauro and coworkers
[110] conducted a human study in persons with obesity and
metabolic syndrome in order to test if exogenous ghrelin
could improve the balance between NO and endothelin-1,
a vasoconstrictor peptide produced by vascular endothelial
cells. In the absence of ghrelin, the vasodilator response to
BQ-123, an endothelin A receptor antagonist, was greater in
patients than in controls; whereas infusion of NO synthase
inhibitor induced smaller vasoconstriction in patients than
in controls [110]. Exogenous ghrelin decreased the vasodila-
tor response to BQ-123 and enhanced the magnitude of
changes in forearm blood ﬂow induced by NO synthase
inhibitor in patients but not in controls [110]. The favorable
eﬀectofghrelinonendothelinA-dependentvasoconstriction
was likely related to the stimulation of NO production,
because no change in the vascular eﬀect of BQ-123 was
observed after ghrelin in persons with metabolic syndrome
during continuous infusion of the NO donor sodium
nitroprusside. In patients with metabolic syndrome, ghrelin
has beneﬁts to normalize the balance between vasoconstric-
tor (endothelin 1) and vasodilating (NO) mediators, thus
suggesting that this peptide has important peripheral actions
to preserve vascular homeostasis in humans [110].
9. GhrelinO-Acetyltransferase (GOAT)
The peptide hormone ghrelin is the only known protein
modiﬁed with an O-linked octanoyl side group, which
occurs on its third serine residue. This modiﬁcation is
crucial for ghrelin’s physiological eﬀects including regulation
of feeding, adiposity, and insulin secretion [4]. It is no
longer than two years ago when an enzyme ghrelin O-
acyltransferase (GOAT), which links octanoate to Ser3 of
ghrelin, was discovered by two diﬀerent research groups
[111, 112]. Human GOAT is able to acylate ghrelin also with
other fatty acids, besides octanoate, ranging from acetate
to tetradecanoid acid [112]. Analysis of the mouse genome
revealed that GOAT belongs to a family of 16 hydrophobic
membrane-bound acyltransferases and is the only member
of this family that octanoylates Ser3 position of ghrelin
peptide when coexpressed in cultured endocrine cell lines
with prepro-ghrelin [111, 112]. Expression levels of gastric
GOAT are the highest under ad libitum and are decreased
with fasting, showing similar pattern of decrease to thatInternational Journal of Peptides 5
Table 2: Associations of polymorphisms in the GHRL gene.
SNP Risk allele Association Subjects References
Leu72Met Met72 Lower age of onset of self-reported obesity 96 obese and 96 normal-weight
Swedish women [72]
Leu72Met Met72
Higher frequency in Whites than in Blackslower
BMI, fat mass, visceral fat, total TG and RQ;
higher IGF-1 levels in Blacks
784 French-Canadian subjects
(Quebec Family Study) 778 subjects
(276 Blacks and 502 Whites;
HERITAGE Family Study) [73]
Arg51Gln Gln51 Not observed among Blacks
1442 subjects (741 from obese registry,
701 from normal reference
population; SOS)
Leu72Met Met72 Higher BMI, earlier age of onset of obesity and
reduced ﬁrst phase insulin secretion 70 tall and obese children [74]
Gln90Leu Gln90 Higher frequency in obese children, but also in
underweight students
215 extremely obese German children
and adolescents, 93 normal-weight
students,134 underweight students, 44
normal-weight adults
[75]
Leu72Met Met72 Lower serum creatinine and lipoprotein a levels 258 Finnish Caucasians with T2D and
522 controls [76]
Arg51Gln Gln51
Risk allele for hypertension and T2D; predictor of
2-h plasma glucose in OGTT; lower IGF-1 and
higher IGFBP-1 concentrations in normotensives;
lower AUC insulin
519 hypertensive and 526
normotensive Finnish Caucasians [77]
Leu72Met Met72
In obese/overweight: higher neonatal
weight-for-age; earlier age at onset of obesity;
higher IGF-1 concentration
81 obese or overweight and 96
normal-weight Italian children and
adolescents and 72 normal-weight
young adults
[6]
4427G>AG D i ﬀuse large cell lymphoma
684 healthy controls and 308 North
American subjects with non-Hodgkin
Lymphoma
[78]
Arg51Gln Gln51 Lower MetS frequencyHigher fasting glucose,TG,
and frequency of MetS and lower HDL cholesterol 856 Old Order Amish from US [79] Leu72Met Met72
Leu72Met Met72
More depressed and anxious in patients with
methamphetamine dependence. No association
with methamphetamine dependence
118 Koreans with methamphetamine
dependence, 144 controls [80]





C Lower HDL cholesterol
All four SNPs: no association with T2D 760 T2D and 641 nondiabetic Koreans [82]
Leu72Met Leu72 Higher TG, fasting insulin and HOMA-IR. Higher
fasting insulin and HOMA-IR
1420 Caucasians (500 normal weight
and 920 overweight/obese) [83]
−604 >C/T C
Leu72Met Met72
Lower allele frequency in diabetic nephropathy
with renal dysfunction. Lower total cholesterol
levels in patients with diabetic nephropathy with
renal dysfunction
138 subjects with diabetic
nephropathy, 69 diabetics without
nephropathy
[84]
Leu72Met Met72 Lower creatinine levels in diabetic group. No
association with T2D 206 T2D, 80 controls [28]
−501A>CA H i g h e r B M I
1045 Finnish subjects from the Oulu
Project Elucidating Risk for
Atherosclerosis (OPERA) study
[85]
Leu72Met No association with weight loss 771 obese Caucasian Europeans [86]
Leu72Met Met72
Higher allele frequency in higher BMI group than
in normal-weight group. Higher BMI, waist
circumference, and change in body weight from
age 18
2238 middle-aged and older Japanese
people [87]6 International Journal of Peptides
Table 2: Continued.
SNP Risk allele Association Subjects References
Leu72Met Met72
Lower BMI in CAD patients but no association
with CAD, no association with hypertension,
T2D, or dyslipidaemia
317 Chinese CAD patients, 323
controls [88]
Leu72Met Met72 Higher scores on Drive for Thinness-Body
Dissatisfaction subscale 264 Japanese women
[89]
3056T >C C
Higher weight, BMI, fat mass, waist
circumference, sum of skinfold thicknesses,




Higher cholesterol levels over time. Subjects with
Gln51and /or Met72 lost body weight faster than
patients with Arg51/Leu72
210 hemodialysed patients
prospectively followed up to 15
months
[90]
Leu72Met Met72 Persons with 72Met allele have lower risk to
develop T2DM
507 persons with IGT: the Finnish
diabetes prevention study [91]
−604G/A G Persons with the most common genotype
combination of the SNPs 604G/-501A/,
Leu72/GLN90 have signiﬁcantly lower systolic
and diastolic blood pressure at baseline and
during the 3-year follow-up
507 persons with IGT: the Finnish




of ghrelin [112]. GOAT expression is localized in ghrelin
producing cells in gastric mucosa [112–114]a sw e l la si n
pancreas [111, 112]. It has been found that the genetic
disruption of the GOAT gene in mice leads to complete
absence of AG in circulation [112].
Kirchner and coworkers have recently studied the role of
GOAT in regulating of the activity of ghrelin using diﬀerent
animal models [115]. They showed that GOAT functions
as a gastric lipid sensor linking selected ingested nutrients
with hypothalamic energy balance regulation via endocrine
ghrelin system[115]. Animal models have shown that GOAT
is required and suﬃcient to mediate the impact of dietary
lipids on body adiposity, and that activation of the GOAT-
ghrelinsystemistriggeredbyalipid-richenvironmentrather
than by caloric depreviation [115]. Speciﬁcally, suﬃcient
dietary supply of medium chain triglycerides is important
for ghrelin acylation [115].
The discovery of GOAT has provided possibilities to
develop tools to study speciﬁc functional roles of the two
diﬀerent ghrelin forms, UAG and AG, in human health in
more detail. For example, modiﬁcation of its expression
providestoolstostudythefunctionofdiﬀerentghrelinforms
and makes possible to develop drugs against obesity and
related conditions.
10. Therapeutic PotentialagainstObesity and
InsulinResistance by Targeting
GOAT/GhrelinSystem
Increasing prevalence of obesity throughout the world is
becoming an increasing health burden. Because obesity
is a strong risk factor for development of cardiovascular
diseases and T2DM, the development of strategies to combat
obesity epidemic is urgently needed. AG and UAG forms
o fg h r e l i na sw e l la sG O A Ta r ea t t r a c t i v et a r g e t st od e v e l o p
pharmacological treatments for obesity and diabetes.
Pharmaceutical companies have started actively to
develop drugs that can target orexigenic or obesity related
functions of ghrelin, its receptor, or GOAT [116–119]. Ghre-
linreceptorantagonistsareshowntoblockGHsecretionand
thus improve the diabetic condition by promoting glucose-
dependent insulin secretion and weight loss and suppressing
appetite[120].PeptideinverseagonistDLys3-GHRP6,which
blocksGHRPinducedGHsecretion,isshowntoreducefood
intake and body weight. Furthermore, vaccination of mature
rats or mouse with ghrelin immunoconjugates against AG
decreases feed eﬃciency, adiposity, and body weight gain in
relation to immune response elicited against AG [121, 122].
Recently, a new class of L-RNA-based hormone antagonists,
the spiegelmers (SPMs), has been developed [123]. SPMs
are L-isomer oligonucleotides that are stable in biological
ﬂuids, enabling long-lasting peptide neutralization after a
single application [123]. This makes these compounds very
useful for experimental purposes and possibly as therapeutic
agents. Unlike classic hormone antagonists, SPMs do not
interact with the receptor but bind with high aﬃnity to
their target molecule and prevent binding to the endogenous
receptor. The antighrelin Spiegelmer NOX-B11-3 neutralizes




Several genome-wide scans have suggested that certain areas
of the chromosome 3, the same chromosome where ghrelin
and ghrelin receptor genes are located, might be linked with
obesity or metabolic syndrome [72, 73]. Polymorphisms in
the human GHRL gene and the 5  ﬂanking region have beenInternational Journal of Peptides 7
intensively studied. The most studied exonic SNPs include
the Leu72Met located in exon 3 and Arg51Gln, which is
located in exon 3 within the last codon of the mature ghrelin
proteinanddisruptstherecognitionsiteoftheendoprotease,
leading to proteolytic cleavage of the carboxy-terminal 66
amino acids to produce mature ghrelin [74], Table 1.
Most of the association studies are focused on metabolic
syndrome and T2DM, which are summarized in Table 2.A
number of studies have shown associations between GHRL
SNPs and obesity or related traits, although the results are
contradictory (see Table 2). The Met72 allele of GHRL has
been associated with earlier age at onset of obesity and
higher BMI [6, 74, 78, 87, 88, 91, 125, 126], but negative
ﬁndings have also been reported [6, 74, 77, 78, 85, 89]. The
−501A>C in the promoter region of the GHRL gene and
the intronic +3056T>C polymorphisms has been shown to
associate with obesity and related conditions [79, 81], while
some studies have failed to ﬁnd association with these SNPs
[6, 79, 81, 85, 92, 127–129].
In addition, ghrelin variations are also shown also to be
associated with blood pressure [129].
Regarding the genetic association studies of GHSR SNPs,
only a few studies have been reported so far. From these
reports at least two have shown an association between
GHSR SNPs and features of metabolic syndrome [75, 76],
but most of the studies have shown negative results.
12. Take-Home Message
In terms of obesity, metabolic syndrome, and T2DM, ghrelin
is very interesting hormone, which plays a crucial role in
glucose and insulin metabolism and in development of
obesity and insulin resistance. The knowledge on functions
of ghrelin in peripheral tissues, such as pancreas, adipose,
and vascular tissues has increased during the last few
years. The recent discovery, the characterization of ghrelin-
O-acyltransferase, GOAT has provided new challenges to
develop drugs against obesity and T2D. The modiﬁcation
of GOAT expression provides tools to regulate the AG:UAG
ratio and to study the speciﬁc roles of diﬀerent ghrelin forms
(AG and UAG) separately in human health. Regarding the
positive cardiovascular eﬀects of ghrelin, it is considered as a
direct target for prevention of CVD.
Regarding the genetics of ghrelin and its receptors, more
studies are needed to show whether and to what extent they
are involved in the pathogenesis of metabolic syndrome and
T2DM. In Genome wide association studies no conﬁrmation
has been achieved in this regard.
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